The PRO-ACT database Design, initial analyses, and predictive features

Neurology

Volumn 83, Issue 19, 2014, Pages 1719-1725

  Atassi, Nazem ^a   Berry, James ^a   Shui, Amy ^b   Zach, Neta ^c   Sherman, Alexander ^a   Sinani, Ervin ^a   Walker, Jason ^a   Katsovskiy, Igor ^a   Schoenfeld, David ^b   Cudkowicz, Merit ^a   Leitner, Melanie ^c  

^a Department of Neurology   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Prize4Life   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; RILUZOLE; URIC ACID;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BODY MASS; DEMOGRAPHY; DISEASE COURSE; FAMILY HISTORY; FEMALE; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RATING SCALE; REVISED AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; SURVIVAL TIME; VITAL CAPACITY; VITAL SIGN; CLINICAL TRIAL (TOPIC); DATA BASE; INFORMATION PROCESSING; LONGITUDINAL STUDY; METHODOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; STATISTICS AND NUMERICAL DATA;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; DATABASE MANAGEMENT SYSTEMS; DATASETS AS TOPIC; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; OBSERVATIONAL STUDY AS TOPIC; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN;

EID: 84921985362     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000951     Document Type: Article

References (39)

1. Rowland L, Shneider N. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
2. McGuire V, Longstreth W Jr, Koepsell T, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 1996;47: 571-573.
3. Cudkowicz M, Katz J, Moore D, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:259-265.
4. Molenberghs G, Kenward MG. The Direct Likelihood Method: Missing Data in Clinical Studies. Hoboken, NJ: John Wiley & Sons; 2007:75-92.
5. Bhattacharjee Y. Pharma firms push for sharing of cancer trial data. Science 2012;338:29.
6. Fischer JS, Rudick RA, Cutter GR, Reingold SC; Force NMSCOAT. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 1999; 5: 244-250.
7. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72:705-711.
8. Gordon PH, Salachas F, Lacomblez L, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegenerative Dis 2013;12:81-90.
9. Sherman AV, Gubitz AK, Al-Chalabi A, et al. Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14: 53-61.
10. Gomeni R, Fava M. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotem-poral Degener 2014;15:119-129.
11. Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 2009;285:95-99.
12. Paganoni S, Zhang M, Quiroz Zárate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 2012;259:1923-1928.
13. Bogdanov M, Brown RH, Matson W, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000;29:652-658.
14. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010;48:629-641.
15. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 2012;51:1501-1508.
16. Chen X, Wu G, Schwarzschild M. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep 2012;12:367-375.
17. Ascherio A, LeWitt PA, Xu K, et al. URate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-1468.
18. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716-723.
19. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord 2010;25:224-228.
20. Lawton K, Cudkowicz M, Brown M, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler 2012;13:110-118.
21. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills A-M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011;44:20-24.
22. Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A, Group FTS. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:163-167.
23. Chiò A, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 2011;77:1432-1437.
24. Miller RG, Anderson FA, Bradley WG, et al. The ALS patient care database: goals, design, and early results. Neurology 2000;54:53.
25. Cudkowicz ME, Shefner JM, Simpson E, et al. Arimoclo-mol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008;38: 837-844.
26. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004;63: 1656-1661.
27. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60:22-31.
28. Miller R, Moore DH, Young L, Group WS. Placebo-controlled trial of gabapentin in patients with amyotro-phic lateral sclerosis. Neurology 1996;47:1383-1388.
29. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481-488.
30. BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999;52:1427-1433.
31. ALS CNTF Treatment Study (ACTS) Group. A double blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46: 1244-1249.
32. Bensimon G, Lacomblez L, Meininger V; The ALSRSG. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
33. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002;249: 609-615.
34. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-784.
35. Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:266-271.
36. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61: 456-464.
37. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler 2005;6:37-44.
38. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis: ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Mot Neuron Disord 2001;2:9-18.
39. Meininger V, Bensimon G, Bradley WG, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Mot Neuron Disord 2004;5:107-117.